Integrated Genomic and Transcriptomic Profiling Reveals Distinct Biological Programs and Therapeutic Opportunities in Cancer of Unknown Primary

Background: Cancer of unknown primary (CUP) is a metastatic, heterogeneous malignancy accounting for 2-5% of cancer diagnoses globally. Failure to identify the primary site precludes tumor-type-specific therapy and, together with an aggressive clinical course, contributes to poor survival. The biological mechanisms driving these behaviors remain poorly understood. A deeper understanding of CUP biology is therefore essential to improve diagnostic precision and therapeutic strategies. To address this knowledge gap, we comprehensively characterized the multi-omics landscape of CUP and identified biological and potentially therapeutic targets beyond tissue-of-origin (ToO) assignment. Methods: Whole-genome sequencing (WGS) data from 283 CUP patients were analyzed for ToO predictions, mutational signatures, driver alterations, genetic immune escape (GIE), and clinically actionable alterations. Matched RNA-sequencing (RNA-seq) data from 79 cases were used to characterize functional gene expression signatures and define transcriptomic subtypes. Clinical, WGS, and RNA-seq data were integrated via weighted gene co-expression network analysis (WGCNA). Results: High-confidence ToO predictions (likelihood >80%) were obtained for 58% of CUPs, most commonly predicting lung, gastrointestinal, and biliary tract origins. Mutational signatures clustering revealed four subgroups dominated by tobacco smoking, defective DNA mismatch repair (dMMR), UV exposure, and APOBEC activity, while a fifth group, comprising most tumors (n=169; 60%), showed mixed mutational processes. The cohort also frequently exhibited mutations in established cancer driver genes, including TP53, CDKN2A, KRAS, and epigenetic modifiers ARID1A, SMARCA4, and ARID2. GIE alterations occurred in 35% of tumors, mostly involving HLA-I genes. Transcriptomic profiling defined five subtypes with different degrees of immune infiltration, fibrosis, and tumor proliferation. These subtypes were not significantly associated with clinical or genomic features, indicating that the tumor microenvironment (TME) represents another layer of CUP heterogeneity. WGCNA further linked proliferative programs to cell-cycle, DNA-replication, and neuroendocrine features. WGS data identified potentially targetable alterations in 64% of the CUP patients. Conclusions: CUP comprises biologically heterogeneous tumors with diverse predicted origins, mutational histories, and TME subtypes. Transcriptomic profiling and integrated genomics suggest that immune escape and rapid proliferation contribute to the clinical aggressive behavior. Together, these findings provide a molecular framework for understanding CUP heterogeneity and support therapeutic stratification by both ToO predictions and tumor-specific molecular alterations.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-17
DOI
https://doi.org/10.64898/2026.11.14.26368097
Primary Topic
Cancer Diagnosis and Treatment
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Integrated Genomic and Transcriptomic Profiling Reveals Distinct Biological Programs and Therapeutic Opportunities in Cancer of Unknown Primary

Michael Leenders, Harmen J.G. van de Werken, Dwin G.B. Grashof, Yes A.J. van de Wouw et al.
2 links
medRxiv
Cancer Diagnosis and Treatment
preprint

Integrated Genomic and Transcriptomic Profiling Reveals Distinct Biological Programs and Therapeutic Opportunities in Cancer of Unknown Primary

Michael Leenders, Harmen J.G. van de Werken, Dwin G.B. Grashof, Yes A.J. van de Wouw, Debbie G. J. Robbrecht, Pétur Snæbjörnsson, Rosan Olsman, Peter D Katsikis, Wenya Wang, Lidy Scheffers
preprint en

Abstract

Background: Cancer of unknown primary (CUP) is a metastatic, heterogeneous malignancy accounting for 2-5% of cancer diagnoses globally. Failure to identify the primary site precludes tumor-type-specific therapy and, together with an aggressive clinical course, contributes to poor survival. The biological mechanisms driving these behaviors remain poorly understood. A deeper understanding of CUP biology is therefore essential to improve diagnostic precision and therapeutic strategies. To address this knowledge gap, we comprehensively characterized the multi-omics landscape of CUP and identified biological and potentially therapeutic targets beyond tissue-of-origin (ToO) assignment. Methods: Whole-genome sequencing (WGS) data from 283 CUP patients were analyzed for ToO predictions, mutational signatures, driver alterations, genetic immune escape (GIE), and clinically actionable alterations. Matched RNA-sequencing (RNA-seq) data from 79 cases were used to characterize functional gene expression signatures and define transcriptomic subtypes. Clinical, WGS, and RNA-seq data were integrated via weighted gene co-expression network analysis (WGCNA). Results: High-confidence ToO predictions (likelihood >80%) were obtained for 58% of CUPs, most commonly predicting lung, gastrointestinal, and biliary tract origins. Mutational signatures clustering revealed four subgroups dominated by tobacco smoking, defective DNA mismatch repair (dMMR), UV exposure, and APOBEC activity, while a fifth group, comprising most tumors (n=169; 60%), showed mixed mutational processes. The cohort also frequently exhibited mutations in established cancer driver genes, including TP53, CDKN2A, KRAS, and epigenetic modifiers ARID1A, SMARCA4, and ARID2. GIE alterations occurred in 35% of tumors, mostly involving HLA-I genes. Transcriptomic profiling defined five subtypes with different degrees of immune infiltration, fibrosis, and tumor proliferation. These subtypes were not significantly associated with clinical or genomic features, indicating that the tumor microenvironment (TME) represents another layer of CUP heterogeneity. WGCNA further linked proliferative programs to cell-cycle, DNA-replication, and neuroendocrine features. WGS data identified potentially targetable alterations in 64% of the CUP patients. Conclusions: CUP comprises biologically heterogeneous tumors with diverse predicted origins, mutational histories, and TME subtypes. Transcriptomic profiling and integrated genomics suggest that immune escape and rapid proliferation contribute to the clinical aggressive behavior. Together, these findings provide a molecular framework for understanding CUP heterogeneity and support therapeutic stratification by both ToO predictions and tumor-specific molecular alterations.

medRxiv
Radboud University Nijmegen (NL), Erasmus MC (NL), The Netherlands Cancer Institute (NL), VieCuri Medisch Centrum (NL), Máxima Medisch Centrum (NL)
China Scholarship Council
Good health and well-being
Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon